TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Ezetimibe Plus Simvastatin Versus Simvastatin in Untreated Subjects With High Cholesterol (P03435)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* \>=18 years and \<= 75 years of age~* LDL-C concentration \>= 3.3 mmol/L (130 mg/dL) to \<= 4.9 mmol/L (190 mg/dL) at baseline.~* Triglyceride concentration \<3.99 mmol/L (350 mg/dL) at baseline.~* Documented coronary heart disease (CHD), which will include one or more of the following features: documented stable angina (with evidence of ischemia on exercise testing); history of MI; history of PCI (primarily PTCA with or without stent replacement); symptomatic peripheral vascular disease; documented history of atherothrombotic cerebrovascular disease; and/or documented history of non-Q wave MI.~* Stable weight history for at least 4 weeks prior to entry into study at baseline.~* Female subjects of childbearing potential must be using an acceptable method of birth control or be surgically sterilized.~Exclusion Criteria:~* Body mass index (BMI) \>=35 kg/m\^2 at baseline.~* Subjects whose liver transaminases (ALT, AST) are \>1.5 times the upper limit of normal and with active liver diseases at baseline.~* Subjects with evidence of current myopathy (including subjects with CK\>1.5 times above the upper limit of normal) at baseline.~* Subjects with clinical laboratory tests (CBC, blood chemistries, urinalysis) outside the normal range that are clinically acceptable to the investigator at baseline.~* Subjects with Type II diabetes mellitus who are poorly controlled (HbA1c\>9%) or newly diagnosed (within 3 months) or who have had a change in anti-diabetic therapy within 3 months of baseline.~* Subjects with Type I diabetes mellitus who have not been on a stable insulin regimen for 3 months prior to baseline, or who have a recent history of repeated hypoglycaemia or unstable glycaemic control.~* Subjects who have known hypersensitivity to HMG-CoA reductase inhibitors.~* Female subjects who consume \>14 units and male subjects who consume \>21 units of alcohol per week.~* Female subjects who are pregnant or breast feeding.~* Subjects who have not observed the designated washout periods for any of the prohibited medications.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Ezetimibe + Simvastatin (Type: EXPERIMENTAL): None
- Simvastatin (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Rituximab and Chemotherapy Followed by Ibritumomab Tiuxetan as Treatment for Low Grade Follicular Non-Hodgkin's Lymphoma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~To be included in this study, you must meet the following criteria:~* Histologic documentation of follicular center, B-cell lymphoma~* Early stage lymphoma (stages I or II) relapsed after radiation therapy alone~* No previous chemotherapy or monoclonal antibody therapy~* Measurable or evaluable disease~* Able to perform activities of daily living with minimal assistance~* Age \> 18 years~* Adequate bone marrow ,liver and kidney function~* Must be accessible for treatment and follow-up.~* Bone marrow examination initial staging and accurate restaging~* All patients must give written informed consent prior to study entry.~Exclusion Criteria:~You cannot participate in this study if any of the following apply to you:~* Small lymphocytic (CLL type) lymphomas and CLL~* Impaired bone marrow reserve~* Female pregnant or lactating~* Serious active infection at the time of treatment~* Any other serious underlying condition~* Central nervous system involvement (brain or meningeal)~* HIV or AIDS-related lymphoma~* Received prior external beam radiation therapy to \> 25% of active bone marrow~* Pleural effusion~* Received prior murine antibodies or proteins~* History of other neoplasms within five years of diagnosis~Please note: There are additional inclusion/exclusion criteria. The study center will determine if you meet all of the criteria. If you do not qualify for the trial, study personnel will explain the reasons. If you do qualify, study personnel will explain the trial in detail and answer any questions you may have.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Does Dehydro Epiandrosterone (DHEA) Improve Pregnancy Rate in Women Undergoing IVF/ICSI With Expected Poor Ovarian Response?

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Women undergoing IVF/ICSI treatment with expected poor ovarian response according to the Bologna criteria~Exclusion Criteria:~* Women with BMI \>35 Kg/M2~* Women with a single ovary~* Known allergy to DHEA~* Diabetic women on insulin as insulin lowers DHEA levels and might reduce the effectiveness of DHEA supplements

- Gender: FEMALE
- Minimum Age: 20 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- DHEA (Type: ACTIVE_COMPARATOR): women will receive DHEA 6 weeks before starting IVF/ICSI
- Control (Type: NO_INTERVENTION): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Yoga and Bolus Lukewarm Saline as Rapid Colonoscopy Preparation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient scheduled to undergo elective complete colonoscopy as an outpatient.~* Aged 18 or older.~* The patient gives written informed consent and can understand the information given.~* The patient can participate in the study only once.~Exclusion Criteria:~* Sodium chloride sensitivity.~* Limitation to exercise.~* Earlier resection of the large bowel or rectum.~* Known active colitis.~* Ileus or gastrointestinal obstruction.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Study Arms:
- BLS and Yoga exercise (Type: ACTIVE_COMPARATOR): Patients will take a bolus intake of 8 oz. (240mL) to 16 oz. (480mL) of lukewarm saline water and perform yoga poses.
- PEG (HalfLytely) (Type: ACTIVE_COMPARATOR): Patients followed the preparation method according to the manufacturer's standard instructions.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Shared Decision-Making for Colorectal Cancer Screening

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Asymptomatic average-risk subjects~* Under the direct care of one of participating site's staff (attending) physicians or physician extenders;~* No prior screening other than fecal occult blood testing (FOBT);~* No major co-morbidities that preclude CRC screening by any method~Exclusion Criteria:~* Prior CRC screening by any method other than FOBT occult blood testing~* High-risk condition (personal history of colorectal cancer or polyps, family history of colorectal cancer or polyps involving one or more first degree relatives, chronic inflammatory bowel disease)~* Lack of fluency in written and spoken English (since decision aid and personalized risk assessment tool will be in English only due to funding issues);~* Comorbidities that preclude CRC screening by any method

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Decision aid plus YourDiseaseRisk (Type: EXPERIMENTAL): Patients viewed the decision aid and completed the Your Disease Risk risk assessment tool prior to visit with their primary care provider.
- Decision aid alone (Type: EXPERIMENTAL): Patient's viewed decision aid only prior to a visit with their primary care provider.
- III (Type: SHAM_COMPARATOR): Standard care

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Tezepelumab Home Use Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female, age 12 to 80 years.~* Documented physician-diagnosed asthma for at least 12 months.~* Evidence of asthma as documented by post BD (albuterol/salbutamol) reversibility of FEV1 ≥ 12% AND ≥200 mL (15-60 min after administration of 4 puffs of albuterol/salbutamol), documented either: in the previous 12 months prior to V1, OR demonstrated at V1, V1A, or at V2.~* Documented history of current treatment with medium- or high-dose ICS for at least 6 months and at least one additional asthma controller medication according to standard practice of care. ICS dose must be greater than or equal to 500 μg/day fluticasone propionate dry powder formulation or equivalent daily.~* Morning pre-BD FEV1 of \>50% predicted normal at Visit 1, Visit 1A, or Visit 2.~Exclusion Criteria:~* Clinically important pulmonary or systemic diseases other than asthma.~* History of cancer except basal cell carcinoma, squamous cell carcinoma, or in situ carcinoma of the cervix within 12 months prior to Visit 1.~* Acute upper or lower respiratory infection requiring antibiotics or antiviral medications finalized \<2 weeks before Visit 1 or during screening/run-in period.~* A helminth parasitic infection diagnosed within 6 months that is untreated or is unresponsive to the standard of care.~* Smoking history of ≥10 pack years, (includes vaping and e-cigarettes)~* History of chronic alcohol or drug abuse.~* Tuberculosis requiring treatment within 12 months prior to V1.~* History of HIV, Hepatitis B or Hepatitis C.~* Receipt of any marketed or investigational biologic agent within 4 months or 5 half-lives (whichever is longer) prior to visit 1 or receipt of any investigational non-biologic agent within 30 days or 5 half-lives.~* Bronchial thermoplasty in 24 months prior to V1.~* Anaphylaxis or documented immune complex disease (Type III hypersensitivity reactions) to any biologic therapy.~* Evidence of active liver disease (e.g. jaundice, AST, ALT or ALP \>2 times upper limit of normal), ongoing liver disease or inexplicably elevated liver chemistry values.~* Pregnant, breastfeeding or lactating women.~* Non-leukocyte depleted whole blood transfusion in 120 days prior to visit 1.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Tezepelumab (AI) (Type: EXPERIMENTAL): Tezepelumab subcutaneous injection, administered by Autoinjector (AI) device.
- Tezepelumab (APFS) (Type: EXPERIMENTAL): Tezepelumab subcutaneous injection, administered by Accessorized pre-filled syringe (APFS).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Three Doses of Aclidinium Bromide Compared to Placebo and to an Active Comparator in Chronic Obstructive Pulmonary Disease (COPD) Patients.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~1. Males and non-pregnant, non-lactating females aged ≥ 40.~2. Patients with a clinical diagnosis of stable moderate to severe COPD, according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines: (http://www.goldcopd.com) and stable airway obstruction. Post-salbutamol FEV1/FVC \< 70% at Screening Visit (Visit 1) (i.e., 100xpost-salbutamol FEV1/FVC \<70%).~3. Current, or ex-cigarette smoker with a smoking history of at least 10 pack-years.~4. Patient whose FEV1 at the Screening Visit measured between 10-15 minutes post inhalation of salbutamol is 30% \< FEV1 \<80% of the predicted normal value (i.e., 100 x Post-salbutamol FEV1/ Predicted FEV1 must be \< 80% and ≥ 30%).~5. Female patients at least 1 year post-menopausal, surgically sterile (defined as having a hysterectomy or tubal ligation), or practicing a medically approved and highly effective method of contraception.~6. Patients who understand the study procedures and are willing to participate in the study as indicated by signing the informed consent.~Exclusion Criteria:~1. History or current diagnosis of asthma.~2. Clinically significant respiratory conditions other than COPD at the time of Inform Consent signature~3. Hospitalisation due to COPD exacerbation within the previous 3 months.~4. Signs of a COPD exacerbation or respiratory infection (including the upper respiratory tract) within the previous 6 weeks.~5. Clinically significant cardiovascular conditions~6. Presence of symptomatic prostatic hypertrophy and/or bladder neck obstruction.~7. Presence of narrow-angle glaucoma.~8. QTcB) above 470 milliseconds in the ECG performed at Screening Visit,~9. Patient who does not maintain regular day/night, waking/sleeping cycles

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Aclidinium bromide 100 μg bid (Type: EXPERIMENTAL): Aclidininum bromide 100 μg twice daily by inhalation
- Aclidininum bromide 200 μg bid (Type: EXPERIMENTAL): Aclidininum bromide 200 μg twice daily by inhalation
- Aclidininum bromide 400 μg bid (Type: EXPERIMENTAL): Aclidininum bromide 400 μg twice daily by inhalation
- Placebo (Type: PLACEBO_COMPARATOR): Placebo twice-daily by inhalation
- Formoterol 12 μg bid (Type: ACTIVE_COMPARATOR): Formoterol 12 μg twice daily by inhalation

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A 14 Week Study of Mindfulness Effects on Attentional Control in Older Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Able to provide informed consent and perform cognitive and behavioral (mindfulness) interventions;~* Time and willingness to commit to the completion of this study;~* Ability to read at an 8th grade level based on scores on the Wechsler Test of Adult Reading (WTAR) and reading text at 14 point font~Exclusion Criteria:~* Lack of time and willingness to commit to the completion of this 14-week study~* Less than an 8th grade education~* Having been told by a healthcare provider that they (1) have had a stroke or mini-stroke in the past 12 months, (2) have ever had a traumatic brain injury, (3) have had schizophrenia or psychosis, (4) have problem with alcohol or substance abuse~* extreme difficulty reading ordinary print in a newspaper, or have stopped reading due to poor eyesight.~* extreme difficulty hearing, or being completely unable to hear, ordinary speech in low-noise conditions, even with hearing aid.~* Currently participating in cognitive training or brain training~* Having participated in any cognitive or brain training study within the last 6 months~* Currently participating in yoga or meditation based practices

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Brain Health (Type: ACTIVE_COMPARATOR): In weeks 1 and 14, participants receive: Montreal Cognitive Assessment (MoCA), Wechsler Test of Adult Reading (WTAR), Functional Activities Questionnaire (FAQ), Older Americans Resources and Services (OARS) Complete Activities of Daily Living Scale, The Short Form (36) Health Survey (SF-36), Attention measures (Attention Network Test (ANT); Continuous Performance Test (CPT); Auditory Dual Task (ADT); Mind wandering; Cued Stroop), Positive and Negative Affect Scale (PANAS), Geriatric Depression Scale (GDS), Mindfulness Attention Awareness Scale (MAAS), Five Facet Mindfulness Questionnaire (FFMQ), Emotion Regulation Questionnaire (ERQ), State-Trait Anxiety Inventory (STAI), and Starkstein Apathy Scale (AS). In weeks 4-11, participants receive the Brain Health control instruction.
- Mindfulness-inspired Treatment/Testing (Type: EXPERIMENTAL): Participants receive all of the same measures as the active comparator Brain Health condition in Weeks 1-14. In weeks 4-11, participants receive Mindfulness Inspired Treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Meta-Iodobenzylguanidine (123I-mIBG) Scintigraphy Imaging in Patients With Heart Failure and Control Subjects Without Cardiovascular Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Study subjects must be adults with an established diagnosis of heart failure (New York Heart Association Class II or III) and reduced left ventricular ejection fraction (LVEF) (≤ 35%) or be healthy volunteers without heart disease.~Exclusion Criteria:~* Healthy volunteers were not eligible if they had a history of diabetes mellitus, signs/symptoms of neurological disease (e.g., Parkinson's Disease, multiple system atrophy, Parkinsonian syndromes), or other diseases known to affect the sympathetic nervous system.~* Subjects with New York Heart Association Class I or IV heart failure were not eligible.~* Subjects were excluded if they had previously received 123I-mIBG or 131I-mIBG or participated in a clinical study involving investigational medicinal product or devices within 30 days.~* Subjects that had a pacemaker or had received defibrillation, anti-tachycardia pacing or cardioversion to treat a previous arrhythmic event or had an ICD inserted within 30 days before study entry are not eligible.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- 123I-mIBG (meta-iodobenzylguanidine) (Type: EXPERIMENTAL): Single dose

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Phase 3 Study of VX-445 Combination Therapy in Cystic Fibrosis (CF) Subjects Heterozygous for F508del and a Gating or Residual Function Mutation (F/G and F/RF Genotypes)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Subject has a confirmed diagnosis of CF and is heterozygous for F508del and either a gating or residual function mutation (F/G and F/RF genotypes)~* Forced expiratory volume in 1 second (FEV1) value ≥40% and ≤90% of predicted mean for age, sex, and height~Key Exclusion Criteria:~* Clinically significant cirrhosis with or without portal hypertension~* Lung infection with organisms associated with a more rapid decline in pulmonary status~* Solid organ or hematological transplantation~Other protocol defined Inclusion/Exclusion criteria may apply

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Control: IVA or TEZ/IVA (Type: ACTIVE_COMPARATOR): Following an IVA or TEZ/IVA run-in period of 4 weeks, participants either received IVA 150 milligrams (mg) every 12 hours (q12h) or TEZ 100 mg once daily (qd)/IVA 150 mg q12h in the treatment period for 8 weeks.
- TC: ELX/TEZ/IVA (Type: EXPERIMENTAL): Following an IVA or TEZ/IVA run-in period of 4 weeks, participants received ELX 200 mg qd/TEZ 100 mg qd/IVA 150 mg q12h in the treatment period for 8 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Flexible-dose Brexpiprazole as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder, the Delphinus Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female outpatients 18 to 65 years of age, inclusive, at the time of informed consent.~* Subjects with both a diagnosis of MDD, and in a current major depressive episode, as defined by DSM-IV-TR criteria~* Subjects willing to discontinue all prohibited psychotropic medications to meet protocol-required washouts prior to and during the trial period.~Exclusion Criteria:~* Females who are breast-feeding and/or who have a positive pregnancy test result during screening prior to receiving trial medication~* Subject has a current Axis I (DSM-IV-TR) diagnosis of: dementia, Schizophrenia, Bipolar, Eating disorder , Obsessive-compulsive disorder, Panic disorder, Posttraumatic stress disorder~* Subjects experiencing hallucinations, delusions or any psychotic symptomatology in the current major depressive episode.~* Subjects who have met DSM-IV-TR criteria for substance abuse or dependence within the past 180 days~* Subjects currently treated with insulin for diabetes.~* Subjects with uncontrolled hypertension~* Subjects with known ischemic heart disease or history of myocardial infarction, congestive heart failure, angioplasty, stenting, or coronary artery bypass Surgery~* Subjects with a positive drug screen for cocaine, marijuana, or other illicit drugs~* Inability to swallow tablets or tolerate oral medication~* Abnormal laboratory test results, vital signs and ECG results~* Subjects who previously participated in any prior brexpiprazole clinical trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Placebo + ADT (Type: PLACEBO_COMPARATOR): Matching Placebo and assigned ADT
- Brexpiprazole + ADT (Type: EXPERIMENTAL): Brexpiprazole, flexible dose and assigned ADT
- Seroquel XR + ADT (Type: ACTIVE_COMPARATOR): Seroquel XR, flexible dose and assigned ADT

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete